FR2387035A1 - NEW MEDICINAL PRODUCT INTENDED IN PARTICULAR FOR THE TREATMENT OF FUNCTIONAL CEREBRAL DISORDERS - Google Patents

NEW MEDICINAL PRODUCT INTENDED IN PARTICULAR FOR THE TREATMENT OF FUNCTIONAL CEREBRAL DISORDERS

Info

Publication number
FR2387035A1
FR2387035A1 FR7710906A FR7710906A FR2387035A1 FR 2387035 A1 FR2387035 A1 FR 2387035A1 FR 7710906 A FR7710906 A FR 7710906A FR 7710906 A FR7710906 A FR 7710906A FR 2387035 A1 FR2387035 A1 FR 2387035A1
Authority
FR
France
Prior art keywords
treatment
medicinal product
product intended
new medicinal
cerebral disorders
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
FR7710906A
Other languages
French (fr)
Other versions
FR2387035B1 (en
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cassenne Laboratoires
Original Assignee
Cassenne Laboratoires
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cassenne Laboratoires filed Critical Cassenne Laboratoires
Priority to FR7710906A priority Critical patent/FR2387035A1/en
Priority to IL54462A priority patent/IL54462A0/en
Priority to JP4135578A priority patent/JPS53130440A/en
Priority to GB14173/78A priority patent/GB1556851A/en
Priority to IT48852/78A priority patent/IT1102581B/en
Priority to GR55954A priority patent/GR72116B/el
Priority to BE186726A priority patent/BE865891A/en
Priority to PT67885A priority patent/PT67885B/en
Priority to DE2815878A priority patent/DE2815878C2/en
Priority to NL7803895A priority patent/NL7803895A/en
Publication of FR2387035A1 publication Critical patent/FR2387035A1/en
Application granted granted Critical
Publication of FR2387035B1 publication Critical patent/FR2387035B1/fr
Granted legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Abstract

Médicament caractérisé en ce qu'il renferme de la 1,3-dimétyl 3,7-dihydro 7-(5' oxo-hexyl)1H-purine 2,6-dione et de la dihydroergocristine ou l'un de ses sels d'addition avec les acides minéraux ou organiques pharmaceutiquement acceptables, compositions renfermant le médicament précité à titre de principe actif.Drug characterized in that it contains 1,3-dimetyl 3,7-dihydro 7- (5 'oxo-hexyl) 1H-purine 2,6-dione and dihydroergocristine or one of its salts addition with pharmaceutically acceptable mineral or organic acids, compositions containing the above-mentioned drug as active principle.

FR7710906A 1977-04-12 1977-04-12 NEW MEDICINAL PRODUCT INTENDED IN PARTICULAR FOR THE TREATMENT OF FUNCTIONAL CEREBRAL DISORDERS Granted FR2387035A1 (en)

Priority Applications (10)

Application Number Priority Date Filing Date Title
FR7710906A FR2387035A1 (en) 1977-04-12 1977-04-12 NEW MEDICINAL PRODUCT INTENDED IN PARTICULAR FOR THE TREATMENT OF FUNCTIONAL CEREBRAL DISORDERS
IL54462A IL54462A0 (en) 1977-04-12 1978-04-06 Pharmaceutical compositions intended especially for the treatment of functional disorders of the brain, comprising purine derivatives
JP4135578A JPS53130440A (en) 1977-04-12 1978-04-10 Novel pharmaceutical composition having obuect to treat especially functional disorder of brain
IT48852/78A IT1102581B (en) 1977-04-12 1978-04-11 PHARMACEUTICAL COMPOSITIONS PARTICULARLY USEFUL IN THE TREATMENT OF FUNCTIONAL BRAIN TURBES
GB14173/78A GB1556851A (en) 1977-04-12 1978-04-11 Pharmaceutical compositions
GR55954A GR72116B (en) 1977-04-12 1978-04-11
BE186726A BE865891A (en) 1977-04-12 1978-04-11 NEW PHARMACEUTICAL COMPOSITIONS INTENDED IN PARTICULAR FOR THE TREATMENT OF CEREBRAL FUNCTIONAL DISORDERS
PT67885A PT67885B (en) 1977-04-12 1978-04-11 TICS, IN PARTICULAR FOR THE TREATMENT OF FUNCULAR DISORDERS
DE2815878A DE2815878C2 (en) 1977-04-12 1978-04-12 Pharmaceutical compositions based on 1,3-dimethyl-3,7-dihydro-7- (5'-oxo-hexyl) -IH-purine-2,6-dione and dihydroergocristine
NL7803895A NL7803895A (en) 1977-04-12 1978-04-12 NEW PHARMACEUTICAL PREPARATIONS PARTICULARLY FOR THE TREATMENT OF FUNCTIONAL CEREBRAL DISORDERS.

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR7710906A FR2387035A1 (en) 1977-04-12 1977-04-12 NEW MEDICINAL PRODUCT INTENDED IN PARTICULAR FOR THE TREATMENT OF FUNCTIONAL CEREBRAL DISORDERS

Publications (2)

Publication Number Publication Date
FR2387035A1 true FR2387035A1 (en) 1978-11-10
FR2387035B1 FR2387035B1 (en) 1980-03-21

Family

ID=9189287

Family Applications (1)

Application Number Title Priority Date Filing Date
FR7710906A Granted FR2387035A1 (en) 1977-04-12 1977-04-12 NEW MEDICINAL PRODUCT INTENDED IN PARTICULAR FOR THE TREATMENT OF FUNCTIONAL CEREBRAL DISORDERS

Country Status (10)

Country Link
JP (1) JPS53130440A (en)
BE (1) BE865891A (en)
DE (1) DE2815878C2 (en)
FR (1) FR2387035A1 (en)
GB (1) GB1556851A (en)
GR (1) GR72116B (en)
IL (1) IL54462A0 (en)
IT (1) IT1102581B (en)
NL (1) NL7803895A (en)
PT (1) PT67885B (en)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2511598A1 (en) * 1981-08-24 1983-02-25 Gauri Kailash PHARMACEUTICAL PRODUCT COMPRISING A BLOOD CIRCULATION-ACTIVATING SUBSTANCE IN COMBINATION WITH A DEPRINED CALF BLOOD DIALYSIS CONCENTRAT
EP0173039A2 (en) * 1984-07-19 1986-03-05 BEECHAM - WUELFING GmbH & Co. KG Use of xanthine and thioxanthine derivatives for the preparation of medicaments
EP0267676A2 (en) * 1986-09-11 1988-05-18 Beecham Wuelfing GmbH & Co KG Use of 1,3-di-n-butyl-7-(2-oxypropyl) xanthine in the treatment of cerebrovascular or cerebral senility associated disorders, peripheral vascular disease and proliferative skin diseases

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI81258C (en) * 1982-02-01 1990-10-10 Sandoz Ag FOERFARANDE FOER FRAMSTAELLNING AV EN PHARMACEUTISK KOMPOSITION FOER NASAL ADMINISTRATION.

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2511598A1 (en) * 1981-08-24 1983-02-25 Gauri Kailash PHARMACEUTICAL PRODUCT COMPRISING A BLOOD CIRCULATION-ACTIVATING SUBSTANCE IN COMBINATION WITH A DEPRINED CALF BLOOD DIALYSIS CONCENTRAT
EP0173039A2 (en) * 1984-07-19 1986-03-05 BEECHAM - WUELFING GmbH & Co. KG Use of xanthine and thioxanthine derivatives for the preparation of medicaments
EP0173039A3 (en) * 1984-07-19 1988-09-14 BEECHAM - WUELFING GmbH & Co. KG Use of xanthine and thioxanthine derivatives for the preparation of medicaments
EP0267676A2 (en) * 1986-09-11 1988-05-18 Beecham Wuelfing GmbH & Co KG Use of 1,3-di-n-butyl-7-(2-oxypropyl) xanthine in the treatment of cerebrovascular or cerebral senility associated disorders, peripheral vascular disease and proliferative skin diseases
EP0267676A3 (en) * 1986-09-11 1990-04-04 Beecham Wuelfing GmbH & Co KG Use of 1,3-di-n-butyl-7-(2-oxypropyl) xanthine in the treatment of cerebrovascular or cerebral senility associated disorders, peripheral vascular disease and proliferative skin diseases

Also Published As

Publication number Publication date
DE2815878C2 (en) 1986-10-09
IT1102581B (en) 1985-10-07
JPS627167B2 (en) 1987-02-16
IL54462A0 (en) 1978-07-31
GR72116B (en) 1983-09-15
PT67885B (en) 1980-04-07
BE865891A (en) 1978-10-11
FR2387035B1 (en) 1980-03-21
NL7803895A (en) 1978-10-16
DE2815878A1 (en) 1978-10-19
GB1556851A (en) 1979-11-28
JPS53130440A (en) 1978-11-14
PT67885A (en) 1978-05-01
IT7848852A0 (en) 1978-04-11

Similar Documents

Publication Publication Date Title
DE3779500D1 (en) LEVODOPA METHYL ESTER CONTAINING PHARMACEUTICAL COMPOSITIONS, THEIR PRODUCTION AND THERAPEUTIC USE.
FR2364030A1 (en) PHARMACEUTICAL COMPOSITIONS BASED ON ANTHOCYANIDINES AND PROCESS FOR THEIR PREPARATION
FR2512670B1 (en) CAPSULES CONTAINING THE ACTIVE INGREDIENT OF AN ALLERGEN AND PROCESS FOR THEIR PREPARATION
ES2137948T3 (en) ADVANCED SYSTEM OF ADMINISTRATION OF MEDICINES AND METHOD OF TREATMENT OF PSYCHIATRIC, NEUROLOGICAL AND OTHER DISORDERS WITH CARBAMACEPINE.
ES8301632A1 (en) An orally administered drug form comprising a polar bioactive agent and an adjuvant.
BE902874A (en) THERAPEUTIC COMPOSITIONS AND METHOD FOR THE TREATMENT OR PREVENTION OF PAF-ACETHER-CAUSED DISEASES
NO20022442D0 (en) Medicines for diseases related to reduction in bone mass
BE899564A (en) PHARMACEUTICAL COMPOSITION FOR PARENTERAL ADMINISTRATION BASED ON NIMODIPIN AND PROCESS FOR ITS PREPARATION.
DE3480053D1 (en) A kit or device and method for administering gangliosides and derivatives thereof of inhalation and pharmaceutical compositions suitable therefor
IL97796A0 (en) Pharmaceutical compositions containing n-alkylated 1,4-dihydropyridine-dicarboxylic acid esters,certain such compounds and their preparation
FR2356425A1 (en) APPLICATION AS MEDICINAL PRODUCTS FROM ORGANIC DERIVATIVES OF MONTMORILLONITE
FR2387035A1 (en) NEW MEDICINAL PRODUCT INTENDED IN PARTICULAR FOR THE TREATMENT OF FUNCTIONAL CEREBRAL DISORDERS
FR2422640A1 (en) NEW 8B-ALKYL SUBSTITUTE MORPHINANE-6-ONES, THEIR PRODUCTION PROCESS AND THE MEDICINAL PRODUCT CONTAINING THEM
FR2407928A1 (en) QUINAZOLINE DERIVATIVES FOR USE AS ANTIHYPERTENSE MEDICINES AND PROCESS FOR THEIR PREPARATION
FR2392023A1 (en) NEW TRANS-5-ARYL-2,3,4,4A, 5,9, B-HEXAHYDRO-1H-PYRIDO (4,3-B) INDOLES, THEIR PREPARATION PROCESS AND PHARMACEUTICAL COMPOSITION CONTAINING THEM
KR880004810A (en) Peptic Ulcer Treatment
FR2645747B1 (en) NOVEL PHARMACEUTICAL COMPOSITIONS, THEIR PROCESS FOR OBTAINING AND THEIR USE IN TUMOR THERAPEUTICS
FR2408589A1 (en) NEWS 13,14-BISDESHYDROPROPROSTAGLANDINS, THEIR PREPARATION PROCESS AND THEIR THERAPEUTIC APPLICATIONS
FR2354767A1 (en) NEW PHARMACEUTICAL COMPOSITIONS CONTAINING THIADIAZOLIC DERIVATIVES
FR2374036A1 (en) PHARMACEUTICAL COMPOSITIONS CONTAINING 3-PHENOXYPYRIDINE
FR2398048A1 (en) NEW PHYSIOLOGICALLY ACTIVE PEPTIDES, PROCESS FOR THE PREPARATION OF THEY AND PHARMACEUTICAL COMPOSITION INCLUDING APPLICATION
FR2373522A1 (en) NEW ESTERS OF SUBSTITUTED BENZENESULPHONIC ACIDS, THEIR PREPARATION PROCESS AND THE MEDICINAL PRODUCT CONTAINING THEM
FR2424027A1 (en) NEW MEDICINAL PRODUCT, IN PARTICULAR SEDATIVE AND SLEEP INDUCER AND PHARMACEUTICAL COMPOSITIONS CONTAINING IT
Mendels Transient toxicity with carphenazine hydrochloride
GB1129134A (en) Improvements in compositions containing nicotinates